These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9605089)

  • 1. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.
    Spanier TB; Oz MC; Minanov OP; Simantov R; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 May; 115(5):1179-88. PubMed ID: 9605089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.
    Spanier TB; Chen JM; Oz MC; Edwards NM; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 Nov; 116(5):860-9. PubMed ID: 9806393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective anticoagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time.
    Spanier TB; Oz MC; Madigan JD; Rose EA; Stern DM; Nowygrod R; Schmidt AM
    ASAIO J; 1997; 43(5):M526-30. PubMed ID: 9360098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
    Bel A; Borik W; Davidson S; Helies JM; Stimmer L; Fremes S; Zelenkofske S; Rusconi C; Alexander J; Alexander D; Menasché P; Pepper J
    Eur J Cardiothorac Surg; 2016 Feb; 49(2):682-9. PubMed ID: 25953802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.
    Benedict CR; Ryan J; Wolitzky B; Ramos R; Gerlach M; Tijburg P; Stern D
    J Clin Invest; 1991 Nov; 88(5):1760-5. PubMed ID: 1939660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
    Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
    Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR; Walenga JM; Koza MJ; Pifarré R
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig.
    Himber J; Refino CJ; Burcklen L; Roux S; Kirchhofer D
    Thromb Haemost; 2001 Mar; 85(3):475-81. PubMed ID: 11307818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose.
    Teligui L; Dalmayrac E; Mabilleau G; Macchi L; Godon A; Corbeau JJ; Denommé AS; Bouquet E; Boer C; Baufreton C
    Interact Cardiovasc Thorac Surg; 2014 Jun; 18(6):763-9. PubMed ID: 24632424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass.
    Shigeta O; Kojima H; Hiramatsu Y; Jikuya T; Terada Y; Atsumi N; Sakakibara Y; Nagasawa T; Mitsui T
    J Thorac Cardiovasc Surg; 1999 Aug; 118(2):354-60. PubMed ID: 10425010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Adjusted Calculation Model Allows for Reduced Protamine Doses without Increasing Blood Loss in Cardiac Surgery.
    Kjellberg G; Sartipy U; van der Linden J; Nissborg E; Lindvall G
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):487-93. PubMed ID: 26270199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparinless cardiopulmonary bypass with argatroban in dogs.
    Rikitake K; Okazaki Y; Naito K; Ohtsubo S; Natsuaki M; Itoh T
    Eur J Cardiothorac Surg; 2004 May; 25(5):819-24. PubMed ID: 15082288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
    Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
    J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model.
    Sakai M; Ohteki H; Narita Y; Naitoh K; Natsuaki M; Itoh T
    Cardiovasc Surg; 1999 Mar; 7(2):187-94. PubMed ID: 10353669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.